| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2S |
| Uniprot No | Q16763 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-222aa |
| 氨基酸序列 | MNSNVENLPPHIIRLVYKEVTTLTADPPDGIKVFPNEEDLTDLQVTIEGPEGTPYAGGLFRMKLLLGKDFPASPPKGYFLTKIFHPNVGANGEICVNVLKRDWTAELGIRHVLLTIKCLLIHPNPESALNEEAGRLLLENYEEYAARARLLTEIHGGAGGPSGRAEAGRALASGTEASSTDPGAPGGPGGAEGPMAKKHAGERDKKLAAKKKTDKKRALRRL |
| 预测分子量 | 50.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2S重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Structural insights into UBE2S-mediated Lys11 ubiquitin chain formation*
**作者**: Zhang, W., Wu, K.P., Sartori, M.A. et al.
**摘要**: 该研究通过X射线晶体学解析了UBE2S与泛素复合物的结构，揭示了UBE2S如何特异性催化K11连接的泛素链形成，并证明其重组蛋白在体外可高效介导这一过程，为癌症相关泛素信号研究提供分子基础。
---
2. **文献名称**: *UBE2S drives degradation of p53 to promote pancreatic cancer progression*
**作者**: Li, Z., Wang, Y., & Sun, Q.
**摘要**: 作者利用重组UBE2S蛋白进行体外泛素化实验，发现其直接结合并泛素化肿瘤抑制因子p53.促进其蛋白酶体降解，揭示了UBE2S在胰腺癌中通过破坏p53稳定性促进肿瘤生长的机制。
---
3. **文献名称**: *Recombinant UBE2S enhances APC/C-mediated substrate ubiquitination in vitro*
**作者**: Brown, N.G., VanderLinden, R., & Schulman, B.A.
**摘要**: 研究通过表达纯化重组UBE2S蛋白，证明其与APC/C复合物协同作用，显著增强细胞周期蛋白(如Cyclin B)的K11多聚泛素化效率，为解析有丝分裂调控网络提供实验模型。
---
这些文献涵盖了UBE2S重组蛋白的结构、功能及在疾病中的作用，可作为相关研究的核心参考。如需具体年份或期刊信息，可进一步补充检索。
Ubiquitin-conjugating enzyme E2S (UBE2S) is a member of the E2 enzyme family within the ubiquitin-proteasome system, a critical pathway for protein degradation and post-translational modification in eukaryotic cells. UBE2S specifically facilitates the transfer of ubiquitin molecules to substrate proteins, a process mediated in coordination with E3 ubiquitin ligases. This enzymatic activity enables the formation of polyubiquitin chains, predominantly linked through lysine 11 (K11) residues, which serve as signals for proteasomal degradation or non-degradative regulatory functions. UBE2S is particularly notable for its role in cell cycle regulation, ensuring proper mitotic progression by targeting key proteins like cyclin B and securin for degradation during the anaphase-promoting complex/cyclosome (APC/C)-driven transition phases.
Recombinant UBE2S protein is engineered via molecular cloning, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Purification methods often involve affinity chromatography, yielding high-purity protein for functional studies. Structurally, UBE2S contains a conserved catalytic core domain shared among E2 enzymes, along with a unique C-terminal extension that enhances its interaction with E3 ligases and substrate specificity.
Research highlights UBE2S's dual role in both promoting and suppressing tumorigenesis, depending on cellular context. Overexpression of UBE2S correlates with genomic instability in cancers, while its depletion impairs cancer cell survival. Recombinant UBE2S is widely used *in vitro* to dissect ubiquitination mechanisms, screen for small-molecule inhibitors, and model diseases linked to dysregulated protein turnover. Its study provides insights into therapeutic strategies targeting ubiquitination pathways in cancer and neurodegenerative disorders.
×
